Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OPKO HealthLTS:0KCS 58 EV-to-EBITDA is -27.18 as of Jul. 24, 2026. GuruFocus rates LTS:0KCS with a GF Score™ of 58/100 and a GF Value™ of $1.06 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, OPKO Health ranks worse than 854700% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OPKO Health's enterprise value is $942.3 Mil.
OPKO Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-34.7 Mil. Therefore, OPKO Health's EV-to-EBITDA for today is -27.18.
The historical rank and industry rank for OPKO Health's EV-to-EBITDA or its related term are showing as below:
LTS:0KCS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -126.86 Med: -8.18 Max: 3759.31
Current: -26.86
During the past 13 years, the highest EV-to-EBITDA of OPKO Health was 3759.31. The lowest was -126.86. And the median was -8.18.
LTS:0KCS's EV-to-EBITDA is ranked worse than 100% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.61
vs LTS:0KCS: -26.86
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
OPKO Health (LTS:0KCS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
OPKO Health's PE Ratio (TTM) for today is calculated as:
OPKO Health's share price for today is $1.18.
OPKO Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for OPKO Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0KCS vs PSNL, CDNA, CSTL: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, OPKO Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OPKO Health EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where OPKO Health's EV-to-EBITDA falls into.
OPKO Health's current Enterprise Value is $942.3 Mil.
OPKO Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPKO Health (LTS:0KCS) has a EV-to-EBITDA of -27.18 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OPKO Health. According to the industry distribution chart, OPKO Health ranks #999999 out of 117 companies in the Medical Diagnostics & Research industry.
Is OPKO Health's EV-to-EBITDA too high?
OPKO Health's current EV-to-EBITDA is -27.18. Based on the distribution chart, OPKO Health ranks #999999 out of 117 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, OPKO Health has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's EV-to-EBITDA compare to PSNL and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, OPKO Health ranks #999999 out of 117 companies for EV-to-EBITDA. This places OPKO Health in the lower half of its industry. The industry median EV-to-EBITDA is 14.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.61, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OPKO Health. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OPKO Health's current EV-to-EBITDA is -27.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (LTS:0KCS) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $1.18 — trading 11.3% above its estimated fair value. The current EV-to-EBITDA is -27.18. OPKO Health's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For OPKO Health (LTS:0KCS), the current EV-to-EBITDA is -27.18 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OPKO Health (LTS:0KCS) Overvalued in 2026?
Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued.
The current stock price of $1.18 is trading 11.3% above its estimated GF Value™ of $1.06.
GuruFocus considers OPKO Health to be Modestly Overvalued.
Key valuation signals for LTS:0KCS:
EV-to-EBITDA: -27.18
GF Value™: $1.06 vs. price of $1.18 (11.3% above fair value)
No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
58GF Score
Get the complete analysis for LTS:0KCS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KCS has been successfully added to your 
